Agentic System for Rare Disease Diagnosis

Updated 16 February 2026

Agentic systems for rare disease diagnosis are autonomous AI frameworks that integrate specialized agents for data ingestion, multi-modal analysis, and hypothesis ranking.
They employ modular architectures with iterative reasoning, retrieval-augmented logic, and clinician-in-the-loop controls to refine diagnostic outcomes.
Performance benchmarks demonstrate enhanced accuracy and speed, along with scalable, transparent deployment in clinical settings.

An agentic system for rare disease diagnosis refers to an autonomous or semi-autonomous AI framework composed of specialized, interacting modules (“agents”) that collaboratively perform the end-to-end workflow of patient data ingestion, analysis, hypothesis generation, and diagnostic ranking, typically leveraging recent advances in LLMs, bioinformatics, and multi-modal data integration. These systems address the profound diagnostic challenge posed by rare diseases: high phenotypic heterogeneity, extreme class imbalance, incomplete molecular/clinical knowledge, and the need for expert-level reasoning over limited data. Below, the principal frameworks, computational methodologies, technical modules, performance metrics, and application domains of current agentic diagnosis systems for rare diseases are reviewed.

1. Core Architectures and Orchestration Paradigms

Agentic systems for rare disease diagnosis universally employ explicit modularization—a decomposition into agent types that address specific analytic tasks or data modalities, then coordinate via central orchestration and shared memory.

Multi-agent division of labor: Most systems implement “decomposer–worker–aggregator” patterns, with a central orchestrator decomposing the diagnostic process into subtasks managed by specialized agents: e.g., data preprocessing, phenotype extraction, gene prioritization, evidence retrieval, variant annotation, pathway enrichment, hypothesis scoring, and explanation synthesis (Chen et al., 6 Aug 2025, Qi et al., 3 Feb 2026, Chen et al., 2024, Neeley et al., 30 Jan 2025).
Long/short-term memory: Persistent memory banks or explicit context windows retain patient-specific and prior-case evidence, retrieved on-demand for current diagnostic inference and comparison (e.g., case similarity retrieval, embedding-based memory (Chen et al., 2024, Zhao et al., 25 Jun 2025)).
Iterative and reflective reasoning: Some frameworks implement self-reflective or multi-turn loops, repeatedly invoking agents with updated analytic context to refine predictions, mitigate uncertainty, or rescore hypotheses based on additional evidence and prior outputs (Zhao et al., 25 Jun 2025, Zheng et al., 21 Aug 2025).
Human-in-the-loop controls: Several systems support clinician input for critical thresholds, feature weights, or active learning cycles, ensuring adaptability and clinical relevance.

2. Modality Integration and Evidence Fusion

Handling rare diseases necessitates the integration of heterogeneous data and reasoning sources:

Genomic and transcriptomic analysis: Multi-modal agentic systems combine WES/WGS variant calling, RNA-seq splicing/expression outlier detection (OUTRIDER/FRASER/ASE), and HPO-coded phenotypic information. Central scoring engines (e.g., mixture-of-experts deep nets) or rules-based engines leverage feature vectors composed of allele frequencies, in silico scores, database evidence, and gene constraint measures, with LLM-based agents augmenting interpretation of RNA signatures or literature matching (Qi et al., 3 Feb 2026, Chen et al., 6 Aug 2025).
Phenotype normalization: Automated mapping from unstructured clinical text to HPO terms and computation of phenotype specificity and semantic similarity is handled via agents using hybrid string/embedding matching and transformer-based NER (Neeley et al., 30 Jan 2025, Chen et al., 2024).
External knowledge retrieval: Retrieval-augmented agents query structured disease–symptom ontologies, case report databases, and the published literature, integrating retrieved evidence into reasoning chains or candidate rankings (Zheng et al., 21 Aug 2025, Kim et al., 6 Nov 2025).
Tool-wrapping and external API integration: Agents call established tools (Phenomizer, LIRICAL, Exomiser, DrugBank) programmatically, extract structured outputs, and harmonize with LLM-derived or database-derived evidence (Chen et al., 2024, Qi et al., 3 Feb 2026).

3. Diagnostic Reasoning and Scoring Formalisms

Agentic frameworks employ a combination of mathematically formalized similarity metrics, supervised learning, and ensemble methods for diagnostic hypothesis ranking:

Gene and pathway-level overlap/aggregation: Transcriptomics-driven pipelines use Jaccard indices for gene signature overlap, hypergeometric (FDR-adjusted) significance scoring, and pathway-level similarity metrics integrating multi-database enrichment (Chen et al., 6 Aug 2025).
Rank aggregation and consensus: Multi-agent LLM approaches partition candidate sets into subgroups (“divide-and-conquer”), generate in-group scores, and average across multiple rounds for final consensus, explicitly mitigating positional and literature biases (Neeley et al., 30 Jan 2025).
Mixture-of-expert/fusion models: Diagnostic engines aggregate learned or rule-combined logit scores from multiple evidence "domains" (e.g., DNA, RNA, phenotype, literature), with tiered prioritization based on defined “clinical fit” and “strong evidence” criteria (Qi et al., 3 Feb 2026).
Ensemble-based calibration: Systems such as RareAlert aggregate risk scores and reasoning chains from multiple LLMs, applying supervised ML (e.g., CatBoost) with SHAP-based attribution for feature importance calibration and low-entropy uncertainty reduction, then distill into a compact, locally deployable model (Chen et al., 26 Jan 2026).
Debate protocols: Modular debate agents pit data-driven and knowledge-driven agent views against each other under LLM orchestration, with argumentation synthesized and adjudicated for final ranked output (Zhou et al., 10 Apr 2025).

4. Traceability, Transparency, and Interpretability

Modern agentic systems foreground explicit, verifiable reasoning:

Evidence-linked chains of reasoning: Diagnostic hypotheses are accompanied by stepwise rationales referencing analytic outputs, matched cases, literature PMIDs, tool outputs, and feature contributions. These are formatted as numbered, linkable justifications for each candidate (Zhao et al., 25 Jun 2025, Qi et al., 3 Feb 2026, Kim et al., 6 Nov 2025).
Tiered/confidence labels: Variants and diagnoses are binned into clinical “tiers” (e.g., strong phenotype+RNA evidence, moderate, weak) with accompanying free-text, LLM-generated interpretation labels (Certain, Highly Likely, Tentative) (Qi et al., 3 Feb 2026).
Bias analysis and mitigation: Pipelines integrate randomization, shuffling, frequency-based penalization, and active learning loops to suppress known bias modes in LLM-based gene ranking (Neeley et al., 30 Jan 2025).

5. Performance Benchmarks and Comparative Outcomes

Agentic rare disease diagnostic systems have been externally validated against large and diverse datasets, and their superiority over prior baselines is quantitatively demonstrated.

System	Modality	Top-1 (%)	Top-5 (%)	Reference
DeepRare	Multi-modal	70.6	-	(Zhao et al., 25 Jun 2025)
RareCollab	Multi-modal	46	77	(Qi et al., 3 Feb 2026)
MD2GPS	WES+HPO	66	85	(Zhou et al., 10 Apr 2025)
RareAgents	EHR+Clinical	55.9*	78.1*	(Chen et al., 2024)
Deep-DxSearch	All (retrieval)	52.1	45.8†	(Zheng et al., 21 Aug 2025)
RareScale	Chat/genomic	33.1	74.4	(Schumacher et al., 20 Feb 2025)
RADAR	Imaging	54.4	75.1	(Kim et al., 6 Nov 2025)

*Hit@1/Hit@10 on differential diagnosis. †Acc@5 on OOD rare set.

In specific domains, e.g., Mendelian diagnosis, agentic debate frameworks demonstrate a 30–40 percentage point reduction in mean rank of the true gene versus previous tools. Retrieval-augmented reasoning yields 7–10 percentage point absolute gains in Top-1 imaging diagnosis. Ensemble alignment of LLMs (RareAlert) achieves AUC 0.917, with sensitivity and specificity both exceeding 0.77 and 0.92, respectively (Chen et al., 26 Jan 2026). Agentic systems consistently outperform single-shot LLMs, traditional bioinformatic tools, and manual workflows (Zhao et al., 25 Jun 2025, Zheng et al., 21 Aug 2025).

6. Scalability, Deployment, and Clinical Integration

Agentic frameworks vary in their real-world deployment profiles:

Compute efficiency: Local inference is emphasized for privacy (e.g., RDMA runs all agents on a consumer RTX 3090, inference $<$ 0.10/hour, no PHI leaves site) (Wu et al., 14 Jul 2025).
Web or local UI: Several systems offer clinician-facing web portals supporting case upload, guided inquiry, and interactive reporting, compatible with EHR standards (Zhao et al., 25 Jun 2025).
Containerized microservices: Component agents are typically containerized and orchestrated via asynchronous message bus systems for horizontal scaling (Neeley et al., 30 Jan 2025).
Resource requirements: State-of-the-art systems operate with moderate hardware profiles (8–20 GB memory, moderate GPUs), batch throughput of $>$ 1000 cases/minute for risk screening, and support on-premise deployment behind institutional firewalls for regulatory compliance (Chen et al., 26 Jan 2026, Wu et al., 14 Jul 2025).
Feedback and continual learning: Active-learning and feedback modules accommodate iterative refinement via clinician-in-the-loop protocols (Neeley et al., 30 Jan 2025).

7. Limitations, Open Challenges, and Future Directions

While agentic systems have substantially advanced rare disease diagnostics, several limitations and research directions remain:

Sparse multi-omics: Transcriptomic and metabolomic modalities still lag behind DNA-centric evidence in terms of coverage and impact on clinical ground truth; more paired datasets and robust multimodal fusion strategies are needed (Qi et al., 3 Feb 2026, Chen et al., 6 Aug 2025).
Structural variants/complex genotypes: Most frameworks have limited support for CNV, SV, and other non-SNV variant categories; expansion and tuning for these categories are ongoing (Qi et al., 3 Feb 2026).
Retrieval and provenance: Ensuring verifiable provenance for LLM retrieval outputs and mitigating hallucination in rare contexts is not yet universally solved (Qi et al., 3 Feb 2026).
Zero-shot generalization: Detecting previously unseen rare diseases requires memory-augmented generation and more advanced retrieval and representation learning (Chen et al., 2024).
Clinical adoption: Integration into high-throughput clinical environments, EHR linkage, user training, and human factors remain practical foci (Zhao et al., 25 Jun 2025, Wu et al., 14 Jul 2025).
Continual knowledge integration: Rapid incorporation of newly annotated disease-gene or genotype–phenotype links demands continual learning architectures and robust annotation pipelines (Neeley et al., 30 Jan 2025).